Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9993461 | TRAVERE | Method for treating disorders associated with glomerular function |
Mar, 2030
(5 years from now) |
Filspari is owned by Travere.
Filspari contains Sparsentan.
Filspari has a total of 1 drug patent out of which 0 drug patents have expired.
Filspari was authorised for market use on 17 February, 2023.
Filspari is available in tablet;oral dosage forms.
Filspari can be used as treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression.
Drug patent challenges can be filed against Filspari from 17 February, 2027.
The generics of Filspari are possible to be released after 29 March, 2030.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-389) | Feb 17, 2030 |
New Chemical Entity Exclusivity(NCE) | Feb 17, 2028 |
Drugs and Companies using SPARSENTAN ingredient
NCE-1 date: 17 February, 2027
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression
Dosage: TABLET;ORAL